H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on ObsEva SA (NASDAQ: OBSV) yesterday and set a price target of $28. The company’s shares opened today at $14.98, close to its 52-week high of $15.81.
Selvaraju commented:
“We anticipate top-line data within the next few weeks from the Phase 2b EDELWEISS trial of OBE2109 (linzagolix), ObsEva’s main clinical-stage asset, in women with endometriosis. As a reminder, the broad goal of this study is the identification of two distinct therapeutic dosing options to serve the needs of the large and diverse endometriosis patient population: (1) a dosage with the potential for alleviating patient symptoms with moderate estrogen suppression that does not meaningfully decrease bone mineral density (BMD), thus obviating the need for hormonal add- back therapy (ABT); and (2), a higher dosage that fully or nearly fully suppresses estrogen, which would require ABT to restore estrogen with the purpose of counteracting bone loss.”
According to TipRanks.com, Selvaraju is a 3-star analyst with an average return of 2.3% and a 40.1% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as IntelliPharmaCeutics International, Biospecifics Technologies Corp, and EyePoint Pharmaceuticals Inc.
Currently, the analyst consensus on ObsEva SA is Moderate Buy and the average price target is $25.50, representing a 70.2% upside.
In a report released today, BMO Capital also initiated coverage with a Buy rating on the stock with a $23 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $15.81 and a one-year low of $5. Currently, ObsEva SA has an average volume of 44.57K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
ObsEva SA engages in the development of therapeutic treatments for woman’s reproductive health and pregnancy. It offers biopharmaceutical drugs addressing conditions compromising pregnancy from conception to birth. The company was founded by Ernest Loumaye and André Chollet in November 2012 and is headquartered in Geneva, Switzerland.
